Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of Certolizumab Pegol in Subjects With Active Axial Spondyloarthritis.

Trial Profile

Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of Certolizumab Pegol in Subjects With Active Axial Spondyloarthritis.

Completed
Phase of Trial: Phase III

Latest Information Update: 22 Jul 2017

At a glance

  • Drugs Certolizumab pegol (Primary)
  • Indications Ankylosing spondylitis; Spondylarthritis
  • Focus Registrational; Therapeutic Use
  • Acronyms RAPID-axSpA
  • Sponsors UCB
  • Most Recent Events

    • 17 Jun 2017 Results of four year imaging outcomes presented at the 18th Annual Congress of the European League Against Rheumatism.
    • 14 Jun 2017 According to a UCB media release, four-year imaging results from this study were reported at the Annual European Congress of Rheumatology (EULAR) 2017 and the result were also published in the journal Rheumatology.
    • 13 Jun 2017 Results of four year imaging outcomes published in a UCB Media Release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top